Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolMatthew R. Sydes, Nicholas D. James, David P. Dearnaley et al.|Annals of Oncology|2018Cited by 252
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Carmel Pezaro, Laura Murphy et al.|The Lancet Oncology|2026Cited by 3